Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 7/20 | 0.44 |
| ▸ | MGAM | O43451 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SI | P14410 | 3/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 3/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20900188 | 0.86 | PARP1 (0.60) | HSD17B10ALDH1A1HPGDPARP1MGAM | |
| SCHEMBL20900183 | 0.86 | PARP1 (0.60) | HSD17B10ALDH1A1HPGDPARP1MGAM | |
| SCHEMBL24995382 | 0.80 | HSD17B10 (0.49) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL4125230 | 0.80 | MGAM (0.50) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL19540004 | 0.79 | HSD17B10 (0.45) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL7966359 | 0.79 | MEN1 (0.50) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL1272228 | 0.79 | PSMB8 (0.51) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL28871223 | 0.79 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL6489669 | 0.79 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDKDM4ELMNA | |
| SCHEMBL29967781 | 0.79 | HSD17B10 (0.47) | HSD17B10ALDH1A1HPGDKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007117778-A9 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS INC (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1986747-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | Kalypsys, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | NOS2, NOS1, NQO2 | HSD17B10 576/4885ALDH1A1 1044/4885HPGD 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.